Spermicide N-9 multiplies the risk of AIDS

Article Abstract:

Nonoxynol-9 (N-9), a spermicide used by South African women to protect themselves from the human imuno-deficiency virus (HIV), was found to be responsible for tripling the risk of contracting the aquired immune deficiency virus. N-9 is believed to cause skin irritations that can provide a way for HIV to enter the body. The US Centers for Disease Control and Prevention had earlier cancelled a proposed study of N-9 in the US after failing to sign enough volunteers.

Product information, South Africa, Genito-Urinary Preps NEC, Genitourinary agents

---

3rd major firm offers AIDS drug discounts to Africa

Article Abstract:

Bristol-Myers Squibb announced that it will sell its anti-AIDS drugs at huge discounts to African nations to help alleviate the financial strain of having to care with 25 million people afflicted with HIV/AIDS in Africa. The company said it will offer its Videx and Zerit drugs to African countries for $1 per patient daily, compared to the $16 that US patients pay for these drugs. Bristol-Myers is the third pharmaceutical manufacturer to offer such discounts, following the path of Merck & Co and Indian firm Cipla Ltd.

Public affairs, Africa, Antiinfective Preparations NEC, Anti-infective agents, Bristol-Myers Squibb Co.

---

Simple remedies: sometimes the search for a miracle drug can overlook the one that's already there

Article Abstract:

The American Heart Assn (AHA) released a report in Nov 1999 showing the ability of the ramipril drug, which was introduced in 1991, to save 1 million heart patients from death. The study underscored the need to make scientific inquiry on drug applications and development more exhaustive and help patients make more cost-effective purchases for medicine. The findings at the recent AHA meeting also showed aspirin, which has been identified only as a simple painkiller for a long time, with greater effectiveness compared to more costly prescription drugs.

United States, Science & research, Cardiovascular Preparations, Cardiovascular agents

Similar abstracts:

• Abstracts: Founders say time is right for magazine catering to fathers. Magazine promotions called deceptive
• Abstracts: Cisco results come in short of forecast; company foresees drop in revenue next quarter. Cisco Systems agrees to buy ArrowPoint for $5.7 billion
• Abstracts: Console shootout: the sequel; GameCube or XBox? The games, not the systems, may decide. A Pong redux with sweat and swagger
• Abstracts: Collenette estimates five years for high-speed central rail link. CP looks at railway spinoff
• Abstracts: Liberals urged to keep promise for nationwide daycare system. Quebec gets too much funding, filmmakers say

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.